In addition, a recent study has demonstrated that additional use of liraglutide, a glucagon-like peptide 1 analog, also improved cardiovascular outcomes in patients with type 2 diabetes at high risk [30]. This evidence concerns the gene GCG and type 2 diabetes mellitus.